Early stage molecular diagnostics company NuProbe has announced the closing of a $11 million Series A round of funding led by Sequoia Capital China and Serica Partners to continue its development of ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases.
Boston-based NuProbe has closed an $11m series A funding round, led by Sequoia Capital China and Serica Partners. The company is developing a new type of microchip that can be used to monitor the health of patients in hospitals or clinics without having them wear bulky medical devices. The latest investment will be used to continue clinical trials and for work on developing a commercial product, as well as to expand staffing at NuProbe's US and China offices. Private US biotechnology firms received $1.4bn of Chinese investment during Q1 2018, according to PitchBook.